tert-butyl(3-methoxy-4-nitrobenzyloxy)dimethylsilane | 882430-21-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl(3-methoxy-4-nitrobenzyloxy)dimethylsilane
• 英文别名: tert-butyl-(3-methoxy-4-nitro-benzyloxy)-dimethyl-silane；tert-butyl-(3-methoxy-4-nitrobenzyloxy)dimethylsilane；tert-butyl-[(3-methoxy-4-nitrophenyl)methoxy]-dimethylsilane
• CAS: 882430-21-9
• 化学式: C₁₄H₂₃NO₄Si
• 分子量: 297.426
• InChiKey: KYJSIYOKJBQXLX-UHFFFAOYSA-N

物化性质

• 沸点：
  362.7±27.0 °C(Predicted)
• 密度：
  1.051±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.13
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  64.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl(3-methoxy-4-nitrobenzyloxy)dimethylsilane 在 palladium on activated charcoal 二苯基磷酸 、 四丁基氟化铵 、 氢气 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 (4-isothiocyanatomethyl-2-methoxy-phenyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Analysis of structure–activity relationships for the ‘B-region’ of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists

  摘要：

  The structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N '-[4-(methylsulfonylamino)benzyl]thiourea analogues have been investigated as TRPV1 receptor antagonists. A docking model of potent antagonist 2 with the sensor region of TRPV1 is proposed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.006
• 作为产物：
  描述：

  3-甲氧基-4-硝基苯甲醇 、 叔丁基二甲基氯硅烷 生成 tert-butyl(3-methoxy-4-nitrobenzyloxy)dimethylsilane
  参考文献：
  名称：

  N-（3-酰氧基-2-苄基丙基）-N（'）-[4-（甲基磺酰基氨基）苄基]硫脲类似物作为类香草酸受体拮抗剂的“ B区”的结构活性关系分析：N的发现-羟基硫脲类似物，具有有效的镇痛作用。

  摘要：

  研究了强效和高亲和力类香草醇受体（VR1）铅配体N-（3-酰氧基-2-苄基丙基）-N（'）-[4-（甲基磺酰基氨基）苄基]硫脲在B区的结构修饰。用不同的等排官能团取代硫脲。结构活性分析表明，该系列中的A区是决定激动/拮抗活性的主要因素，而与B区无关。与母体硫脲类似物相比，N（C）-羟基硫脲类似物（12、13）在乙酸扭曲试验中显示出出色的镇痛活性。

  DOI：

  10.1016/j.bmcl.2004.02.002

文献信息

• PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
  申请人：Arora Nidhi

  公开号：US20120015962A1

  公开（公告）日：2012-01-19

  Compounds of the formula I or II: wherein X, m, Ar, R 1 and R 2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

  式I或II的化合物： 其中X，m，Ar，R1和R2如本文所定义。所述化合物对于治疗IRAK介导的疾病是有用的。
• Analysis of structure–activity relationships for the ‘B-region’ of N -(3-acyloxy-2-benzylpropyl)- N ′ -[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: discovery of an N -hydroxythiourea analogue with potent analgesic activity
  作者：Jeewoo Lee、Sang-Uk Kang、Hyun-Kyung Choi、Jiyoun Lee、Ju-Ok Lim、Min-Jung Kil、Mi-Kyung Jin、Kang-Pil Kim、Jong-Hyuk Sung、Suk-Jae Chung、Hee-Jin Ha、Young-Ho Kim、Larry V Pearce、Richard Tran、Daniel J Lundberg、Yun Wang、Attila Toth、Peter M Blumberg

  DOI：10.1016/j.bmcl.2004.02.002

  日期：2004.5

  The structural modifications on the B-region of the potent and high affinity vanilloid receptor (VR1) lead ligand N-(3-acyloxy-2-benzylpropyl)-N(')-[4-(methylsulfonylamino)benzyl]thiourea were investigated by the replacement of the thiourea with diverse isosteric functional groups. Structure-activity analysis indicated that the A-region in this series was the primary factor in determining the agonistic/antagonistic

  研究了强效和高亲和力类香草醇受体（VR1）铅配体N-（3-酰氧基-2-苄基丙基）-N（'）-[4-（甲基磺酰基氨基）苄基]硫脲在B区的结构修饰。用不同的等排官能团取代硫脲。结构活性分析表明，该系列中的A区是决定激动/拮抗活性的主要因素，而与B区无关。与母体硫脲类似物相比，N（C）-羟基硫脲类似物（12、13）在乙酸扭曲试验中显示出出色的镇痛活性。
• METHODS OF DETECTING MYELIN BASIC PROTEIN
  申请人：GENERAL ELECTRIC COMPANY

  公开号：US20140154178A1

  公开（公告）日：2014-06-05

  A method and a kit for detecting myelin basic protein are provided. The method comprises administering an agent, which binds to myelin basic protein (MBP), to a subject at risk of or diagnosed with a myelin-associated neuropathy, and determining myelination by detecting the agent resided in the subject. The amount of the agent present in the subject is indicative of a myelin-associated neuropathy. A method of quantifying an amount of MBP present in a tissue sample is also provided, wherein the method comprises contacting the tissue sample with the same agent, detecting the agent present in the tissue sample; and quantifying an amount of the agent present in the tissue sample.

  提供了一种检测髓鞘碱性蛋白的方法和试剂盒。该方法包括向患有或有风险患上髓鞘相关神经病的受试者施用结合到髓鞘碱性蛋白（MBP）的试剂，并通过检测附着在受试者身上的试剂来确定髓鞘形成情况。受试者中试剂的存在量表明了髓鞘相关神经病的存在。还提供了一种量化组织样本中MBP存在量的方法，其中该方法包括将组织样本与相同的试剂接触，检测组织样本中存在的试剂，并量化组织样本中存在的试剂的数量。
• Methods of detecting myelin basic protein
  申请人：General Electric Company

  公开号：US09040019B2

  公开（公告）日：2015-05-26

  A method and a kit for detecting myelin basic protein are provided. The method comprises administering an agent, which binds to myelin basic protein (MBP), to a subject at risk of or diagnosed with a myelin-associated neuropathy, and determining myelination by detecting the agent resided in the subject. The amount of the agent present in the subject is indicative of a myelin-associated neuropathy. A method of quantifying an amount of MBP present in a tissue sample is also provided, wherein the method comprises contacting the tissue sample with the same agent, detecting the agent present in the tissue sample; and quantifying an amount of the agent present in the tissue sample.

  提供了一种检测髓鞘碱性蛋白的方法和试剂盒。该方法包括向可能患有或已被诊断为髓鞘相关神经病变的受试者注射结合到髓鞘碱性蛋白（MBP）的试剂，并通过检测存在于受试者中的试剂来确定髓鞘形成情况。试剂在受试者中的存在量表明了髓鞘相关神经病变的存在。还提供了一种量化组织样本中MBP存在量的方法，其中该方法包括将组织样本与相同的试剂接触，检测组织样本中存在的试剂，并量化组织样本中存在的试剂量。
• Analysis of structure–activity relationships for the ‘B-region’ of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists
  作者：Jeewoo Lee、Mi-Kyoung Jin、Sang-Uk Kang、Su Yeon Kim、Jiyoun Lee、Myoungyoup Shin、Jaemin Hwang、Sookhyun Cho、Yeon-Sil Choi、Hyun-Kyung Choi、Sung-Eun Kim、Young-Ger Suh、Yong-Sil Lee、Young-Ho Kim、Hee-Jin Ha、Attila Toth、Larry V. Pearce、Richard Tran、Tamas Szabo、Jacqueline D. Welter、Daniel J. Lundberg、Yun Wang、Jozsef Lazar、Vladimir A. Pavlyukovets、Matthew A. Morgan、Peter M. Blumberg

  DOI：10.1016/j.bmcl.2005.06.006

  日期：2005.9

  The structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N '-[4-(methylsulfonylamino)benzyl]thiourea analogues have been investigated as TRPV1 receptor antagonists. A docking model of potent antagonist 2 with the sensor region of TRPV1 is proposed. (c) 2005 Elsevier Ltd. All rights reserved.